Zavegepant (BHV-3500)

Study title/design: Effectiveness and tolerability of zavegepant for acute migraine treatment among those using CGRP targeting preventive medications (NCT06401642) Trial NCT06401642. Recruiting. Estimated completion March 2027 Aim To investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using CGRP-targeting migraine preventive treatments. Study design Phase 4, …

Study title/design: Study of zavegepant in children with migraine (NCT06995729) Trial NCT06995729. Recruiting. Estimated completion 12 August 2027 Aim To learn about the safety and pharmacokinetics of zavegepant in children with a history of migraine. Study design A Phase 1, multicentre, open-label, single-dose study to evaluate the safety, tolerability and pharmacokinetics of zavegepant (one spray …

Study title/design: A study to evaluate the efficacy and safety of oral zavegepant in migraine prevention (NCT04804033) Trial NCT04804033. Terminated for non-safety reasons Aim To compare the efficacy of zavegepant (BHV-3500) to placebo as a preventive treatment for migraine, as measured by reduction in number of migraine days per month (MMD). Study design Phase 2/3, …

Study title/design: Long term safety study of zavegepant (BHV-3500) for the acute treatment of migraine (NCT04408794) Trial NCT04408794. Completed December 23 2021 Aim To evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine. Study design Phase 2/3, open-label, …

Study title/design: Acute treatment trial of zavegepant (BHV-3500) in adults with migraine (NCT03872453) Trial NCT03872453. Completed November 11 2019 Aim To evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine. Study design Phase 2/3, double-blind, randomised, placebo-controlled, dose-ranging …

Study title/design: Randomised trial of zavegepant (BHV-3500) in adults with acute migraine (NCT04571060) Trial NCT04571060. Completed October 22 2021 Aim To test the safety and efficacy of zavegepant (BHV-3500) versus placebo, in the acute treatment of moderate to severe migraine. Study design Phase 3, double-blind, randomised, placebo-controlled, safety and efficacy trial of intranasal zavegepant 10 …